Percheron Therapeutics Announces CEO Succession
Filed with ASX · · 4 pages · English
Percheron Therapeutics Limited on 6ix
Earlier from Percheron Therapeutics
- Quarterly Activities Report and Appendix 4C
- Results of Entitlement Offer
- Prospectus - Non-renounceable Entitlement Offer
- Non-renounceable Entitlement Offer
- Half Yearly Report and Accounts
Later from Percheron Therapeutics
- Notice of date of AGM and other relevant dates
- Application for quotation of securities - PER
- Appendix 4E and Annual Report
- Appendix 4G and Corporate Governance Statement
- Vanderbilt Health to conduct clinical trial of HMBD-002
Follow Percheron Therapeutics into a list and get an email when it puts out news.
Follow Percheron Therapeutics